---
schema_version: "secwatch.filing_event.v1"
accession: "0001724521-24-000090"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T11:47:36.378240+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Arcus Q1 revenue jumps to $145M, net loss $4M; pipeline advances with ASCO presentations and Phase 3 enrollments

## Summary
- Revenue $145M vs $25M YoY, including $135M license revenue from Gilead collaboration amendments.
- Net loss $4M vs $80M YoY; cash $1.1B at quarter end; year-end 2024 cash expected $870-920M.
- R&D expenses $109M (up from $81M); $20M impairment charge for facility sublease.
- Two oral presentations at ASCO 2024: EDGE-Gastric (domvanalimab) and ARC-9 (etrumadenant) in GI cancers.
- Phase 3 STAR-221 enrollment expected mid-2024; STAR-121 H2 2024; first Phase 3 for casdatifan in ccRCC planned H1 2025.

## SEC filing metadata
- accession: 0001724521-24-000090
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000090/0001724521-24-000090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000090/rcus-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001724521-24-000090
- JSON: https://secwatch.observer/filing/0001724521-24-000090.json
- Plain text: https://secwatch.observer/filing/0001724521-24-000090.txt

## Key facts
- Earnings Releases
  Arcus Biosciences, Inc. reported the first quarter ended March 31, 2024 results: revenue $145 million.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $145 million
  - Result: reported results
  source text: to fund operations into 2027. Cash, cash equivalents and marketable securities are expected to be between $870 million and $920 million at the end of 2024. • Revenues were $145 million for the first quarter 2024, compared to $25 million for the same period in 2023. In the first quarter 2024, Arcus recognized $135 million in license and development services
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000090/0001724521-24-000090-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.